Raising the Eptinezumab (Vyepti) Dose to 300 mg: What a Study of Partial Responders Found
A real-world study followed 57 people who only partly responded to eptinezumab (Vyepti) 100 mg. After moving up to 300 mg, about two in three reached a 50% drop in headache days.
On this page · 7 sections
The Question Behind the Study
Eptinezumab (Vyepti) is an anti-CGRP antibody given as an IV infusion every three months. In the US it is approved at two doses, 100 mg and 300 mg, and most people start on 100 mg. A common situation in headache clinics is the person who improves on 100 mg, but not enough. Their headache days drop by about a third instead of by half or more.
At that point the options are to switch to a different preventive or to raise the dose. A new study in Cephalalgia followed people in exactly this situation who moved up to 300 mg. If you are new to this drug class, our explainer on CGRP and the newer migraine drugs covers how they work.
How the Study Was Done
This was a prospective real-world study by the GRASP study group. Adults with high-frequency episodic or chronic migraine who had a hard-to-treat course received two infusions of eptinezumab 100 mg. Those who had a partial response, defined as a 30% to just under 50% drop in monthly headache days from baseline, were moved up to 300 mg for two more quarterly infusions.
The main outcome was the share of people who reached at least a 50% reduction in monthly headache days compared with their original baseline after each 300 mg infusion. The researchers also tracked severe headache days, acute medication use, and two disability scales, MIDAS and HIT-6.
Of the 57 people analyzed, 87.7% were women and the average age was about 48. All had already shown some benefit from 100 mg, so this was a group selected because they were likely to respond further.
What They Found
| Treatment Stage | Estimated Monthly Headache Days | At Least 50% Better Than Baseline |
|---|---|---|
| Baseline (before eptinezumab) | 18.65 | Not applicable |
| After two eptinezumab (Vyepti) 100 mg infusions | 13.33 | None (all were partial responders by design) |
| After first eptinezumab (Vyepti) 300 mg infusion | 10.02 | 57.9% |
| After second eptinezumab (Vyepti) 300 mg infusion | 8.84 | 64.9% |
Each step was a statistically significant improvement over baseline. Severe headache days, acute medication use, and disability scores also improved step by step after the dose increase.
Who was most likely to respond
Two factors predicted reaching a 50% response on 300 mg. People who had a bigger drop in headache days during the 100 mg phase did better after escalation. People who had not previously tried erenumab (Aimovig) were also more likely to respond, which fits with the general pattern that each failed preventive lowers the odds of success with the next one.
Many people track response as a percentage. Our preventive response calculator works out whether you have reached the 30% or 50% marks used in studies like this one.
What This Means in Practice
The authors concluded that raising the dose is a reasonable step before switching treatment in people who partly respond to 100 mg. Since 300 mg is already an approved dose in the US, this does not require off-label use. It also avoids losing the benefit already gained, which can happen during a switch.
Response to anti-CGRP antibodies can also build over several months. Our article on super-responders and when to expect results explains why some people improve slowly, and our review of how long people stay on anti-CGRP drugs shows how often people stop early.
- How much have my monthly headache days dropped since starting eptinezumab (Vyepti)?
- Would 300 mg make sense before switching to another preventive?
- Has my improvement had enough time to show up, or is it still too early to judge?
- Does insurance coverage differ between the 100 mg and 300 mg doses?
Side effects of anti-CGRP antibodies are summarized in our CGRP antibody adverse events chart. People who have had an infusion reaction may find the eptinezumab desensitization protocol helpful.
Limitations
- There was no comparison group. Without people who stayed on 100 mg, it is not possible to separate the effect of the higher dose from continued improvement on the original dose.
- Response to anti-CGRP antibodies often keeps improving over time, so part of the gain may have happened anyway.
- People chosen for a dose increase after a weaker period may improve on their own, an effect known as regression to the mean.
- The study was small, with 57 people, and followed them for two infusion cycles.
- Participants and doctors knew the dose had been raised, which can affect self-reported outcomes.
Key Takeaways
This article is for educational purposes only and does not replace medical advice, diagnosis, or treatment. Talk with your doctor before starting, stopping, or changing any treatment.
References
- Dermitzakis EV, Argyriou AA, Rikos D, et al. Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group. Cephalalgia. 2026;46(10):3331024261498883. doi:10.1177/03331024261498883.
CGRP
Hair Loss and CGRP Migraine Drugs: What the Evidence Shows
A 2026 review gathered every published report of hair loss on CGRP antibodies and gepants. The signal is consistent across the class, the hair loss is usually mild diffuse shedding that reverses after stopping, and th...
CGRP
Groundbreaking study!: Anti-CGRP Monoclonal Antibodies Disease-Modifying!?
A three-year study suggests CGRP antibodies may change the course of migraine.
CGRP
